Skip to main content
. Author manuscript; available in PMC: 2018 Aug 27.
Published in final edited form as: Ann Rheum Dis. 2016 Aug 19;76(3):602–611. doi: 10.1136/annrheumdis-2016-209683

Figure 6. ETC-642 abrogates pro-inflammatory responses of TLR agonist and lupus HDL.

Figure 6.

Pre-incubation of CMϕ (N=8) with ETC-642 (ETC) dampens TLR agonist-induced (A) IL-6 and (B) TNF mRNA synthesis. (C) ETC-642 promotes ATF3 nuclear translocation and blocks inhibitory effects of lupus HDL on ATF3 nuclear localization at a 1:4 ratio in CMϕ (N=6). Quantification is 30min post-stimulation. ETC-642 abrogates lupus HDL-induced (D) IL-6 and (E) TNF synthesis in CMϕ at a 1:4 ratio in CMϕ (N=6). (F) ETC-642 increases ATF3 mRNA at a 1:4 ratio in CMϕ (N=6). Bar graphs are mean ± SEM,* p<0.05, ** p<0.009, *** p<0.0008, **** p<0.0001, ns =non-significant, fold change to media is relative to no HDL treatment.